BFB Health Reports Swing to Profit on Surge in Advertising & E-commerce Revenue in 1H-2026

Bulletin Express09-30

BFB Health Limited released its unaudited interim results for the six months ended 30 June 2026.

Revenue Performance • Group revenue jumped to HK$283.72 million from HK$15.74 million a year earlier, driven by a 2,608.7 % surge in advertising and e-commerce income to HK$280.54 million (98.9 % of total). • Money-lending revenue declined to HK$3.19 million (1.1 % of total), while securities broking generated no income following suspension of operations in September 2023.

Profitability • Gross profit increased to HK$119.70 million (1H-2025: HK$7.64 million); gross margin narrowed to 42.2 % from 48.6 % on higher selling and distribution expenses tied to the e-commerce push. • Profit attributable to shareholders reached HK$9.23 million, reversing a HK$0.83 million loss in the prior period. • Basic and diluted EPS were HK0.8 cent versus a loss of HK0.1 cent. • Segment results: Advertising & e-commerce delivered HK$14.80 million profit; money lending contributed HK$3.49 million; securities broking recorded a HK$0.72 million loss.

Costs and Expenses • Selling and distribution costs rose sharply to HK$88.71 million (1H-2025: HK$0.54 million) due to marketing spend on the “Dyesoo” health-management brand and MCN operations. • Administrative expenses increased 31.0 % to HK$19.67 million. • Fair-value gain on financial assets at FVTPL fell to HK$2.96 million from HK$8.86 million.

Balance Sheet and Liquidity • Total assets stood at HK$598.80 million; net assets improved to HK$231.26 million (31 Dec 2025: HK$222.68 million). • Current ratio remained healthy at 1.53 times with net current assets of HK$187.79 million. • Cash and cash equivalents rose to HK$50.01 million (31 Dec 2025: HK$27.01 million), supported by HK$22.75 million net operating inflow. • Borrowings comprised HK$12.00 million in bonds and HK$10.97 million in other loans; gearing ratio (total liabilities/total assets) was 61.4 %.

Operational Highlights • The Group intensified its focus on digital marketing and MCN services, leveraging the “Dyesoo” health brand across domestic platforms (Taobao, Douyin, JD.com) and overseas channels (TikTok). • Securities brokerage operations remain suspended, and the Group is proceeding with licence surrender to the Securities and Futures Commission. • Money-lending portfolio totalled HK$105.33 million; secured loans accounted for HK$53.60 million, bearing interest rates between 6.0 % and 8.0 % per annum.

Capital Management • No interim dividend was declared. • Proceeds from the 2025 rights issue (HK$39.9 million net) have been fully allocated to bond and payable repayments and working capital. • HK$10.00 million from the 2015 open offer remains earmarked for establishing additional SFO-licensed activities, with utilisation targeted by 31 December 2026.

Outlook Management will prioritise expansion of the high-growth advertising and e-commerce segment while maintaining cautious oversight of the money-lending portfolio and reallocating resources away from non-core securities brokerage operations. No significant post-period events were reported up to the results announcement date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment